**Question:** Monoclonal antibody used for Rheumatoid arthritis:

A. Rituximab
B. Abatacept
C. Infliximab
D. Adalimumab

**Core Concept:**
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation of the synovial joints, leading to joint damage and disability. Monoclonal antibodies are engineered immune system molecules that can target and neutralize specific molecules involved in inflammation and immune response. In the context of RA, they aim to modulate the overactive immune system and reduce joint inflammation.

**Why the Correct Answer is Right:**
The correct answer, **D. Adalimumab**, is a monoclonal antibody targeting TNF-alpha (Tumor Necrosis Factor-alpha), a pro-inflammatory cytokine produced by activated immune cells. TNF-alpha plays a crucial role in the pathogenesis of RA by promoting synovial inflammation, cartilage degradation, and bone erosion. By blocking TNF-alpha, adalimumab helps to reduce RA symptoms and prevent joint damage.

**Why Each Wrong Option is Incorrect:**

A. **Rituximab** is a monoclonal antibody targeting CD20, a B-cell surface antigen involved in B-cell activation and differentiation. Although rituximab can indirectly reduce inflammation in RA by depleting B cells, it does not specifically target TNF-alpha, making it an unsuitable choice for RA treatment.

B. **Abatacept** is a fusion protein that inhibits the interaction between the T-cell co-stimulatory molecule CD80/CD86 and their receptor CD28 on T cells. Although abatacept can reduce joint inflammation, it does not directly target TNF-alpha, making it an unsuitable choice for RA treatment.

C. **Infliximab** is a monoclonal antibody targeting TNF-alpha, similar to adalimumab. However, infliximab is an immune globulin, while adalimumab is a fully humanized monoclonal antibody. The choice between them depends on the patient's preferences and clinical circumstances. In this multiple-choice question, adalimumab is the correct answer due to its direct targeting of TNF-alpha.

**Clinical Pearl:**
Selecting the correct RA treatment is crucial, as it can significantly improve disease activity, joint function, and quality of life for patients. The choice between adalimumab and infliximab depends on factors such as disease severity, patient preference, and potential adverse events. Always consult a rheumatologist for personalized treatment decisions based on patient characteristics and disease severity.